ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Long-term use of blood pressure medication could be contributing to kidney damage

New kidney research from the University of Virginia School of Medicine is raising concerns that long-term use of drugs commonly prescribed to treat high-blood pressure and heart failure could be contributing to kidney damage.

12 Jan 2022

A closer look at the relationship between COVID-19 and Alzheimer’s disease

Researchers discuss the findings of previous studies on the role of SARS-CoV-2 infection in the progression of Alzheimer's Disease.

4 Jan 2022

COVID-19 in association with pre-existing mental and physical health issues

The present study attempts to identify the factors that increase the risk of COVID-19 infection or confer protection against COVID-19 in a study population above 55 years of age known to experience higher morbidity and risk of mortality from COVID-19.

13 Dec 2021

Comparing effectiveness of virus and patients-centered strategies to reduce COVID-19 mortality

Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.

19 Nov 2021

Current understanding of the link between COVID-19 and cardiovascular disease

A review published in Chemo-Biological Interactions has focused on the prevalence of COVID-19 in CVD patients associated with ACE2 mechanisms.

10 Nov 2021

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

A new study aimed to determine whether ACE2 targeting drugs change the tissue levels of ACE2 in healthy mice.

25 Oct 2021

Statin treatment and COVID-19 mortality

The authors highlight the importance of their study in clarifying and expanding the current understanding of the relationship between COVID-19 and statins.

18 Oct 2021

Women with type 2 diabetes and CVD less likely to reach treatment targets than men, study finds

Women with type 2 diabetes and cardiovascular disease (CVD), or at high risk of developing CVD, are less likely to reach recommended treatment targets than men, according to an international study involving almost 10,000 patients with type 2 diabetes, being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), held online this year (27 Sept-1 Oct). Nevertheless, women were less likely to experience adverse CVD outcomes apart from a stroke.

27 Sep 2021

Neurokinin-1 receptor: a potential drug target for the treatment of COVID-19

An opinion article aims to provide evidence that SP could be the possible factor for initiating the cytokine storm during severe SARS-CoV-2 infection.

21 Sep 2021

Early treatment with ACE inhibitors improves cardiac outcomes of patients with Becker muscular dystrophy

There is no consensus on when to introduce cardioprotective treatment in patients with Becker muscular dystrophy (BMD), and practice varies widely.

20 Sep 2021

New ESC guidelines for diagnosis and treatment of heart failure published

The European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure are published online today in European Heart Journal.

27 Aug 2021

Antihypertensives may improve survival for patients with colorectal cancer

Common blood-pressure drugs may improve survival for patients with colorectal cancer, a new study suggests.

19 Aug 2021

More popular type of antihypertensive drugs causes slightly more side effects

Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, but the more popular type causes slightly more side effects, finds a multinational observational study led by researchers at Columbia University Vagelos College of Physicians and Surgeons.

26 Jul 2021

Two types of blood pressure drugs provide equal benefits, but side effects differ

People who are just beginning treatment for high blood pressure can benefit equally from two different classes of medicine - angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) - yet ARBs may be less likely to cause medication side effects, according to an analysis of real-world data published today in Hypertension, an American Heart Association journal.

26 Jul 2021

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host’s microbiome and secondary infection has also been studied.

8 Jul 2021

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Statins are medications widely used in the management of cardiovascular diseases and metabolic syndrome. Statins help lower serum lipids by blocking HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase), the rate-limiting enzyme of cholesterol biosynthesis.

11 Jun 2021

Study reveals mechanisms by which SGLT2 inhibitors produce renoprotective effect

SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.

8 Jun 2021

Oral antidiabetic medication provides kidney protection in focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare form of kidney inflammation (glomerulonephritis) in which the glomeruli become increasingly scarred (sclerotic), leading to progressive loss of kidney function.

7 Jun 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021